Outsourced Pharma Capabilities Update June 2026: Cell Therapy

In this session, leading cell therapy CDMOs will break down how they support programs across development—from early process work through GMP manufacturing, scale-up, and commercial readiness—and where different approaches can reduce downstream risk or introduce it.

This is a focused look at who does what, and where they fit—so you can evaluate partners with greater clarity and move forward with more confidence.